{"entity":{"id":"self-similarity-immune-recognition","kind":"term","name":"Self-similarity and immune-recognition specificity","aka":["peptide self-similarity and immune specificity","TCR cross-recognition"],"tldr":"A receptor may recognize more than one related peptide. Target-selection evidence needs to address recognition of healthy tissue as well as the intended target.","summary":"A primary investigation of an affinity-enhanced MAGE-A3-directed receptor identified cross-recognition of a peptide from titin after unexpected cardiac toxicity. This was a particular engineered-receptor program, not a toxicity rate for all T-cell therapies or neoantigen vaccines. It illustrates why target-gene expression and a sequence match alone are insufficient descriptions of receptor specificity. Proposed-target recognition and off-target recognition need evidence in relevant systems.","asOf":"2026-11-09","links":[{"label":"Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells.","url":"https://doi.org/10.1126/scitranslmed.3006034"},{"label":"Primary evidence for the antigen-presentation teaching distinctions","url":"https://doi.org/10.1182/blood-2013-03-490565"},{"label":"Primary evidence for the antigen-presentation teaching distinctions","url":"https://doi.org/10.1038/s41586-022-04735-9"},{"label":"Primary tolerance mechanism experiment (PubMed 3260350)","url":"https://pubmed.ncbi.nlm.nih.gov/3260350/"},{"label":"Primary tolerance mechanism experiment (PubMed 3029267)","url":"https://pubmed.ncbi.nlm.nih.gov/3029267/"},{"label":"Primary tolerance mechanism experiment (PubMed 7636184)","url":"https://pubmed.ncbi.nlm.nih.gov/7636184/"}],"tags":[],"related":["binding-presentation-recognition","binder-affinity-epitope-developability","tcr-t"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Central and peripheral tolerance include distinct mechanisms. Kisielow and colleagues demonstrated deletion of self-reactive developing cells in an H-Y-receptor transgenic mouse model. Jenkins and Schwartz demonstrated antigen-related unresponsiveness after altered antigen presentation in mouse experiments, and Sakaguchi and colleagues linked a CD4/CD25 regulatory population to prevention of autoimmunity in mice. These are mechanistic examples, rather than universal human response or safety thresholds. A tumour-specific mutation can make a peptide distinguishable from its normal counterpart, but display and a responsive receptor are still needed, and there is no universal percentage of identity that makes a target safe. Higher receptor affinity is not automatically more selective. Receptors can cross-react with peptides from unrelated proteins, as in the titin peptide recognised by the MAGE-A3-directed receptor (Cameron et al., 2013, PMID 23926201; Linette et al., 2013, PMID 23770775). Luksza et al. (Nature 2022, PMID 35589842) modelled neoantigen quality, using non-selfness and selfness, in pancreatic cancer survivors; the model is not a clinical safety rule. In a loaded-peptide concentration series, compare mutant and normal peptides at the same concentration with the same HLA and responder; artificial loading leaves natural processing open and a response threshold is not a patient safety threshold."],"category":"Immunology"},"route":"/terms/self-similarity-immune-recognition/","neighbours":{"term":[{"id":"binder-affinity-epitope-developability","kind":"term","name":"Binder affinity, epitope and developability","route":"/terms/binder-affinity-epitope-developability/"},{"id":"immune-product-evidence","kind":"term","name":"Immune measurements and product evidence","route":"/terms/immune-product-evidence/"},{"id":"neoantigen","kind":"term","name":"Neoantigen","route":"/terms/neoantigen/"},{"id":"binding-presentation-recognition","kind":"term","name":"Peptide binding, presentation and immune recognition","route":"/terms/binding-presentation-recognition/"}],"technology":[{"id":"tcr-t","kind":"technology","name":"TCR-T cell therapy","route":"/technologies/tcr-t/"}],"pathway":[{"id":"antigen-presentation-immunoediting","kind":"pathway","name":"Antigen presentation & immune editing","route":"/pathways/antigen-presentation-immunoediting/"}]}}